文献速递艾滋病与性传播感染

基于整合酶抑制剂的方案在急性HIV-1感染中快速抑制病毒

Rapid viral suppression using integrase inhibitors during acute HIV-1 infection.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

这项单臂96周研究评估了依韦拉韦/考比司他/恩曲他滨/替诺福韦二吡呋酯用于急性HIV-1感染,第24周100%受试者HIV-1 RNA<200拷贝/mL,第48周100%<50拷贝/mL,病毒抑制时间较基于非核苷类逆转录酶抑制剂的历史队列更短;96周体重平均增加3.6 kg,与历史队列的2.4 kg相似。

要点

  • 急性HIV-1感染使用基于整合酶抑制剂的方案可快速持续抑制病毒,第24周100%<200拷贝/mL。
  • 病毒抑制时间较基于非核苷类逆转录酶抑制剂的历史队列更短(中位54天 vs 99天)。
  • 96周体重平均增加3.6 kg,与历史队列的2.4 kg相似。

核心结论

  • 急性HIV-1感染期间使用基于整合酶抑制剂的抗逆转录病毒治疗可实现快速且持续的病毒抑制。
  • 96周内基于整合酶抑制剂的队列体重增加,但与基于非核苷类逆转录酶抑制剂的历史急性HIV-1感染队列体重增加相似。

研究设计与样本

  • 单臂96周研究,评估依韦拉韦/考比司他/恩曲他滨/替诺福韦二吡呋酯每日一次方案用于急性HIV-1感染。
  • 入组33例急性HIV-1感染受试者,31例可分析;大多数为非裔美国人(61%)和男男性行为者(73%),中位年龄26岁(IQR 22-42)。
  • 主要终点为治疗第24周和第48周时HIV-1 RNA<200拷贝/mL和<50拷贝/mL的受试者比例。
  • 同时评估病毒抑制时间和治疗开始后体重增加,并与使用依非韦伦/恩曲他滨/替诺福韦二吡呋酯的基于非核苷类逆转录酶抑制剂的历史急性HIV-1感染队列比较。

主要发现

  • 第24周时,整合酶抑制剂队列100%受试者HIV-1 RNA<200拷贝/mL,非核苷类逆转录酶抑制剂队列99%。
  • 第48周时,两个队列100%受试者HIV-1 RNA<50拷贝/mL。
  • 病毒抑制时间在整合酶抑制剂队列更短(中位54天 vs 99天)。
  • 96周时平均体重变化:整合酶抑制剂队列增加3.6 kg,非核苷类逆转录酶抑制剂队列增加2.4 kg。
  • 两个急性HIV-1感染队列的人口学特征相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiretroviral therapy (ART) is recommended for all individuals with HIV infection, including those with acute HIV-1 infection (AHI). While recommendations are similar to those for chronic infection, efficacy data regarding treatment of acute HIV is limited. METHODS: This was a single arm, 96-week study of a once-daily integrase inhibitor (INSTI)-based regimen using elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) in AHI. Primary endpoint was proportion of participants with HIV-1 RNA <200 copies/mL and <50 copies/mL by treatment weeks 24 and 48, respectively. We also examined time to viral suppression and weight gain after treatment initiation. Outcomes and characteristics were compared with a historical AHI cohort using a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen with efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF). RESULTS: Thirty-three participants with AHI were enrolled with 31 available for analyses. Most were African American (61%) and men who have sex with men (73%). Median age was 26 (IQR 22-42). Demographics were similar between the two AHI cohorts. By Week 24, 100% in the INSTI and 99% in the NNRTI cohort were <200 copies/mL; by Week 48, 100% in both cohorts were <50 copies/mL. Time to viral suppression was shorter in the INSTI cohort (median 54 versus 99 days). Mean weight change was similar with a 3.6 kg increase in the INSTI cohort and 2.4 kg in the NNRTI cohort at 96 weeks. CONCLUSIONS: INSTI-based ART during AHI resulted in rapid and sustained viral suppression. Over 96 weeks, weight increased in the INSTI-based cohort but was similar to weight increase in a historical NNRTI-based AHI cohort.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. McKellar MS, Keys JR, Filiatreau LM, et al. Rapid viral suppression using integrase inhibitors during acute HIV-1 infection. J Antimicrob Chemother. 2025. PMID: 39504491. doi:10.1093/jac/dkae391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。